Elanco Animal Health Incorporated (NYSE:ELAN) Position Increased by Aristeia Capital L.L.C.

Aristeia Capital L.L.C. raised its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 79.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,684 shares of the company’s stock after buying an additional 18,903 shares during the period. Aristeia Capital L.L.C.’s holdings in Elanco Animal Health were worth $517,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of ELAN. FMR LLC grew its holdings in shares of Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company’s stock worth $487,213,000 after acquiring an additional 37,022,891 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Elanco Animal Health by 6.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company’s stock worth $216,774,000 after purchasing an additional 1,074,274 shares in the last quarter. Magnetar Financial LLC raised its holdings in Elanco Animal Health by 13.7% during the 4th quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company’s stock worth $145,711,000 after buying an additional 1,454,082 shares during the period. Geode Capital Management LLC raised its holdings in Elanco Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company’s stock worth $99,102,000 after buying an additional 312,165 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in Elanco Animal Health by 8.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 6,924,098 shares of the company’s stock valued at $83,851,000 after buying an additional 538,631 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the purchase, the director now owns 101,459 shares in the company, valued at $1,105,903.10. The trade was a 10.93 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Price Performance

ELAN opened at $9.75 on Friday. The stock has a fifty day moving average price of $9.89 and a 200 day moving average price of $11.49. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The stock has a market cap of $4.84 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.08 earnings per share. Analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of recent analyst reports. Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Barclays cut their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. UBS Group decreased their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus dropped their price target on Elanco Animal Health from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. Finally, Piper Sandler decreased their price objective on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $14.67.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.